

## SUSPECT ADVERSE REACTION REPORT

## I. REACTION INFORMATION

|  |                                  |  |                               |                         |                                   |   |  |
|--|----------------------------------|--|-------------------------------|-------------------------|-----------------------------------|---|--|
| 1. PATIENT INITIALS<br>(first, last)<br><b>PRIVACY</b>   | 1a. COUNTRY<br><b>COSTA RICA</b> | 2. DATE OF BIRTH<br>Day Month Year<br><b>PRIVACY</b> | 2a. AGE<br><b>38</b><br>Years | 3. SEX<br><b>Female</b> | 3a. WEIGHT<br><b>104.00</b><br>kg | 4-6 REACTION ONSET<br>Day Month Year<br><b>OCT 2024</b> | 8-12 CHECK ALL<br>APPROPRIATE TO<br>ADVERSE REACTION<br><input type="checkbox"/> PATIENT DIED<br><input type="checkbox"/> INVOLVED OR<br>PROLONGED INPATIENT<br>HOSPITALISATION<br><input type="checkbox"/> INVOLVED PERSISTENT<br>OR SIGNIFICANT<br>DISABILITY OR<br>INCAPACITY<br><input type="checkbox"/> LIFE<br>THREATENING<br><input type="checkbox"/> CONGENITAL<br>ANOMALY<br><input type="checkbox"/> OTHER |
| 7 + 13 DESCRIBE REACTION(S) (including relevant tests/lab data)<br>Event Verbatim [PREFERRED TERM] (Related symptoms if any separated by commas)<br>headaches [Headache]<br>felt like nausea [Nausea]<br>vomiting [Vomiting]<br>feel very unwell [Malaise]<br>headaches [Headache]<br>felt a lot of sweating [Hyperhidrosis]<br><br>Case Description: ***This is an auto generated narrative***<br><br>Study ID: 828652-My Healthy Journey |                                  |  |                               |                         |                                   |   |  |

(Continued on Additional Information Page)

## II. SUSPECT DRUG(S) INFORMATION

|  |  |
|--|--|
| 14. SUSPECT DRUG(S) (include generic name)<br>#1 ) Saxenda (liraglutide 6 mg/mL) Solution for injection, 6 mg/mL<br><br>(Continued on Additional Information Page) | 20. DID REACTION<br>ABATE AFTER STOPPING<br>DRUG?<br><br><input type="checkbox"/> YES <input type="checkbox"/> NO <input checked="" type="checkbox"/> NA     |
| 15. DAILY DOSE(S)<br>#1 ) UNK  | 16. ROUTE(S) OF ADMINISTRATION<br>#1 ) Unknown   |
| 17. INDICATION(S) FOR USE<br>#1 ) Weight loss (Weight control)<br><br>(Continued on Additional Information Page)   | 21. DID REACTION<br>REAPPEAR AFTER<br>REINTRODUCTION?<br><br><input type="checkbox"/> YES <input type="checkbox"/> NO <input checked="" type="checkbox"/> NA |
| 18. THERAPY DATES(from/to)<br>#1 ) OCT-2024 / Ongoing  | 19. THERAPY DURATION<br>#1 ) Unknown   |

## III. CONCOMITANT DRUG(S) AND HISTORY

|   |  |  |
|---|--|--|
| 22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction)  |  |  |
| 23. OTHER RELEVANT HISTORY. (e.g. diagnostics, allergies, pregnancy with last month of period, etc.)<br>From/To Dates Type of History / Notes Description<br>Unknown to Ongoing Current Condition Insulin resistance (Insulin resistance)<br>duration not reported<br>Unknown to Ongoing Current Condition Migraine (Migraine)<br>duration not reported |  |  |

## IV. MANUFACTURER INFORMATION

|   |  |
|---|--|
| 24a. NAME AND ADDRESS OF MANUFACTURER<br>Novo Nordisk A/S<br>Lise Grimmeshave<br>Vandtaarnsvej 114<br>Soeborg, DK-2860 DENMARK<br>Phone: +45 44448888 | 26. REMARKS<br>Medically Confirmed: No   |
| 24b. MFR CONTROL NO.<br><b>1422570</b>  | 25b. NAME AND ADDRESS OF REPORTER<br>NAME AND ADDRESS WITHHELD.  |
| 24c. DATE RECEIVED<br>BY MANUFACTURER<br><b>20-MAY-2025</b>   | 24d. REPORT SOURCE<br><input checked="" type="checkbox"/> STUDY <input type="checkbox"/> LITERATURE<br><input type="checkbox"/> HEALTH<br>PROFESSIONAL <input type="checkbox"/> OTHER: |
| DATE OF THIS REPORT<br><b>02-JUL-2025</b>   | 25a. REPORT TYPE<br><input checked="" type="checkbox"/> INITIAL <input type="checkbox"/> FOLLOWUP:   |

02-Jul-2025 11:05

**ADDITIONAL INFORMATION****7+13. DESCRIBE REACTION(S) continued**

Study description: Trial title: This is a 40 weeks digital patient support program with focus on exercise, motivation, nutrition & maintaining strategies (only for patients under Liraglutide 3.0 mg).

Patient's height: 155 cm.

Patient's weight: 104 kg.

Patient's BMI: 43.28824140.

This non-serious Solicited Report from COSTA RICA was reported by a Consumer as "headaches(Headache)" beginning on OCT-2024 , "felt like nausea(Nausea)" beginning on OCT-2024 , "vomiting(Vomiting)" with an unspecified onset date , "feel very unwell(Feeling unwell)" with an unspecified onset date , "headaches(Headache)" with an unspecified onset date , "felt a lot of sweating(Excess sweating)" with an unspecified onset date and concerned a 38 Years old Female patient who was treated with Saxenda (liraglutide 6 mg/mL) from OCT-2024 and ongoing for "Weight loss", "insulin resistance",

Dosage Regimens:

Saxenda: ??-OCT-2024 to Not Reported (Dosage Regimen Ongoing);

Current Condition: Insulin Resistance, Migraine.

Batch Numbers:

Saxenda: ASKU;

Action taken to Saxenda was reported as No Change.

On 2024 the outcome for the event "headaches(Headache)" was Recovered.

On 2024 the outcome for the event "felt like nausea(Nausea)" was Recovered.

The outcome for the event "vomiting(Vomiting)" was Unknown.

The outcome for the event "feel very unwell(Feeling unwell)" was Unknown.

The outcome for the event "headaches(Headache)" was Unknown.

The outcome for the event "felt a lot of sweating(Excess sweating)" was Unknown.

Reporter's causality (Saxenda) -

headaches(Headache) : Possible

felt like nausea(Nausea) : Possible

vomiting(Vomiting) : Unknown

feel very unwell(Feeling unwell) : Unknown

headaches(Headache) : Unknown

felt a lot of sweating(Excess sweating) : Unknown

Company's causality (Saxenda) -

headaches(Headache) : Possible

felt like nausea(Nausea) : Possible

vomiting(Vomiting) : Possible

feel very unwell(Feeling unwell) : Possible

headaches(Headache) : Possible

felt a lot of sweating(Excess sweating) : Unlikely

**14-19. SUSPECT DRUG(S) continued**

| 14. SUSPECT DRUG(S) (include generic name)  | 15. DAILY DOSE(S);<br>16. ROUTE(S) OF ADMIN | 17. INDICATION(S) FOR USE  | 18. THERAPY DATES (from/to);<br>19. THERAPY DURATION |
|---|---|--|--|
| #1 ) Saxenda (liraglutide 6 mg/mL) Solution<br>for injection, 6 mg/mL; Regimen #1 | UNK; Unknown                                | Weight loss (Weight control)<br>insulin resistance (Insulin<br>resistance) | OCT-2024 / Ongoing;<br>Unknown                       |